Effects of candesartan cilexetil on oxidative state and renal function in 5/6 nephrectomized rats

Journal of Human Hypertension

Volumn 13, Issue , 1999, Pages S63-S70

  Sugimoto, Koh Ichi ^a   Tsuruoka, S ^a   Matsushita, K ^a   Fujimura, A ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Antioxidative enzyme; Candesartan cilexetil; Enalapril; Lipid peroxide; Nephrectomized rat

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; CATALASE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLUTATHIONE PEROXIDASE; LIPID PEROXIDE; MALONALDEHYDE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY PARENCHYMA; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; OXIDATION; OXIDATIVE STRESS; PARTIAL NEPHRECTOMY; PROTEIN URINE LEVEL; PROTEINURIA; RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CATALASE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENALAPRIL; GLUTATHIONE PEROXIDASE; KIDNEY; KIDNEY FUNCTION TESTS; MALE; NEPHRECTOMY; ORGAN SIZE; OXIDATION-REDUCTION; PRODRUGS; PROTEINURIA; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; SUPEROXIDE DISMUTASE; TETRAZOLES; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TREATMENT OUTCOME;

EID: 0032905905     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000743     Document Type: Article

References (35)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456 - 1462.
2. Glatras IG, Lau J, Levey AS. Effect of angiotensin-con- verting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trial. Ann Int Med 1997; 127: 337-345.
3. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomemlar fil- tration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
4. Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 1985; 82: 5963-5967.
5. Zatz R Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930.
6. O’Donnell MP Enalapril reduces glomerular injury in obese Zuker rats. Kidney Int 1989; 35: 434.
7. Fogo A Serial micropuncture analysis of glomerular function in two rat models of glomerulosclerosis. J Clin Invest 1988; 82: 322-330.
8. Hostetter TH Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241: F85-F93.
9. CULPEPPER RM, SCHOOLWERTH AC. Remnant kidney oxygen consumption: hypermetabolism or hyperbole? J Am Soc Nephrol 1992; 3: 151-156.
10. Nath KA, Croatt AJ, Hostetter TH. Oxygen consumption and oxidant stress in surviving nephrons. Am J Physiol 1990; 258: F1354-F1362.
11. Mekenzie HS, Troy JL, Renrike HG, Brenner BM. TCV 116 prevents progressive renal injury in rats with extensive renal mass ablation. J Hypertens 1994; 12 (Suppl 9): S11-S16.
12. Zlai F The angiotensin receptor antagonist, irbes- artan, reduces renal injury in experimental chronic renal failure. Kidney Int 1996; 50 (Suppl 57): S132- S136.
13. Watanabe N Urinary protein as measured with a pyrogaloll-red molybdate complex method, manually and in a Hitachi 726 automated analyzer. Clin Chem 1986; 32: 1551-1554
14. Noto A Simple, rapid spectrophotometry of urinary N-acetyl-beta-D-glucosaminidase, with use of a new chromogenic substrate. Clin Chem 1983; 29: 1713-1716.
15. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70: 158-169.
16. Oyanagi Y. Réévaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal Biochem 1984; 142: 290-296.
17. Clairborne A. Catalase activity. In: Greenwood RA (ed). Handbook of Methods for Oxygen Radical Research. CRC Press: Boca Raton, Florida, 1985, pp 283-284.
18. Ohkawa H, Onishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358.
19. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993- 2000.
20. Diamond JR. The role of reactive oxygen species in animal models of glomerular disease. Am J Kidney Dis1992; 19: 292-300.
21. Harris DCH, Chan L, Schrier RW. Remnant kidney hypermetabolism and progression of chronic renal failure. Am J Physiol 1988; 254: F267-F276.
22. Stratta P The role of free radicals in the progression of renal disease. Am J Kidney Dis 1991; 17 (Suppl 1): 33-37.
23. Nath KA, Salahudeen AK. Induction of renal growth and injury in the intact rat kidney by dietary deficiency of antioxidants. J Clin Invest 1990; 86: 1179-1192.
24. De Cavanagh EMV, Fraga CG, Ferder L, Inserra F. Enalapril and captopril enhance antioxidant defenses in mouse tissue. Am J Physiol 1997; 272: R514-R518.
25. Kohara K Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat. Hypertension 1993; 21: 975-979.
26. Okada H Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. J Cardiovase Pharmacol 1995; 26: 564- 569.
27. Shibouta Y TCV-116 inhibits renal interstitial and glomerular injury in glomerulosclerotic rats. Kidney Int 1996; 49 (Suppl 55): S115-S118.
28. Noda M Effects of candesartan cilexetil (TCV- 116) and enalapril in 5/6 nephrectomized rats. Kidney Int 1997; 52 (Suppl 63): S136-S139.
29. Obata J Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats. Kidney Int 1997; 52 (Suppl 63): S229-S231.
30. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int 1996; 49: 578-587.
31. El Dahr SS, Dipps S, Yosipiv IV, Baricos W. Bradykinin stimulates c-fos expression. AP-1-DNA binding activity and proliferation of rat glomerular mesangial cells. Kidney Int 1996; 50: 1850-1855.
32. Yosipiv IV, Dipps S, El Dahr SS. Role of bradykinin B2 receptors in neonatal kidney growth. J Am Soc Nephrol 1997: 8: 920-928.
33. Van Zoelen EJ Bradykinin-induced growth inhibition of normal rat kidney (NRK) cells is paralleled by a decrease in epidermal-growth-factor receptor expression. Biochem J 1994; 298 (Pt 2): 335-40.
34. Keane WF, O’Donnel MP, Kasiske BL, Schmitz PG. Lipids and the progression of renal disease. J Am Soc Nephrol 1990; 1: S69-S74.
35. Kasiske BL, O’Donnell MP, Garvis WJ, Keane WF. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 1988; 62: 367-374.